Recent data about endometrial carcinoma: potential of anti-aromatase agents

[1] Bonte J.: in "Hormones and cancer". Iacobelli S., King R. J.B., Lindner H. R., Lippman H. E. eds., Raven Press, New York, 1980, 443.

[2] Bonte J.: "Developments in endocrine therapy of endometrial and ovarian cancer". Reviews on endocrine-related cancer, 1979, 3, 11.

[3] Bonte J., Ide P., Billiet G., Wynants P.: "Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma". Gynecologic Oncology, 1981, 11, 140.

[4] Bonte J.: "Effects of nolvadex on endometrial adenocarcinoma". Reviews on endocrine-related cancer, 1982, suppl. 11, 35.

[5] Brueggemeier R. W.: "Aromatase inhibitors-mechanisms of steroidal inhibitors". Breast Cancer Res. Treat., 1994, 30, 31.

[6] Brodie A. M. H., Garnett W. M., Hendrickson J.B., et al.: "Inactivation of aromatase in vitro by 4-hydroxy-androstene-3, 17-dione and 4-acetoxy-4-androstene-3, 17-dione and sustained effects in vivo". Steroids, 1981, 38, 693.

[7] Harada N., Hondas I., Hatano 0.: "Aromatase inhibitors and enzyme stability".Reviews on endocrine-related cancer, 1999, 6, 211.

[8] Miller W.R.: "Biology of Aromatase lnhibitors". Pharmacology/Endocrinology, 1999.

[9] Sasano H., Sato S., Ito K., Yajima A., Nakamura J., Yoshihama M. et al.: "Effects of aromatrase inhibitors on the pathobiology of human breast, endometrial and ovarian carcinoma". Reviews on endocrine-related cancer, 1999, 6, 197.

[10] Domber Nowsky P. et al.: "Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared to megestrol acetate". J. Clin. Oncol., 1998, 16, 453.

[11] Buzdar A., Jonat W., Howell A., Jones S., Blomquist C., Vogel S. et al.: ·'Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma". Cancer, 1998, 83, 1142.

[12] Kaufmann M. et al.: "Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer. Results of a phase Ill randomized double-blind trial". J. Clin. Oneal., 2000, 18, 1399.

[13] Paridaens R. et al.: Proceedings of ASCO 2000, 19, 316.

[14] Nabholtz J. M. et al.: "The North American target study, 1999.

[15] Brodie A. et al.: "Preclinical studies using the intratumoral aromatase model ofpostmenopausal breast cancer". Oncology, 1998, 12(3), suppl 5, 36.

[16] Krekels M. D., Wouters W., Van Ginckel R., Janssens B., Callens M., Decoster R.: "Aromatase inhibition by R83842, the dextro isomer of R767 I 3 in jeg 3-choriocarcinoma grown in ovariectomized nude mice". J. Steroid, Biochem. Molec. Biol., 1992, 41(3-8), 761.

[17] Lu Q., Yue W.. Wang S., Liu Y., Long B. and Brodie A "The effects of aromatase inhibitors and anti-estrogens in the nude mouse model" Breast Cancer Research and Treatment, 1998, 50 (1), 63.

[18] Kudoh M., Susaki Y., Ideyama Y., Nanya T., Mori M. and Shikama H.: "Inhibitory effects of a novel aromatase inhibitor, YMS 11, on growth of endometrial explants and insulin-like growth factor-I gene expression in rats with experimental endometriosis". J. Steroid Biochem. Molec. Biol., 1997, 63 (1-3), 75.

[19] Sinha S., Kaseta J., Santers S. J., Demers L. M., Bremmer W. J. and Santen R. J.: "Effect of CGS20267 on ovarian aromatase and gonadotropin levels in the rat". Breast Cancer Research and Treatment, 1998, 48, 45.

[20] Wouters W., Vanginckel R., Krekel S. M., Bowden C. and Decoster R.: "Pharmacology of Vorozole". J. Steroid. Biochem. Malec. Biol., 1993, 44 (4-6), 617.

[21] Iino Y., Karakida T., Sugamata N., Andoh T., Takei H., Takahashi M. et al.: ®Anti tumor effects of SEFI 9, a new non-steroidal aromatase inhi-bitor on 7-12 DMBA - induced mammary tumors in rats". Cancer Research, 1998, 18, 171.

[22] Matsuda A., Higuchi K., Karasawa M., Yoneyama S., Deguchi J., Miyamoto M.: "Fourteen day oral combination dose toxicity study of CGS 16949A with 5-Fluorouracil or tamoxifen in rats". J. of Toxicological Sciences, 1997, 22, 1.

[23] Baum M.: "Use of aromatase inhibitors in the adjuvant treatment of breast cancer". Reviews on endocrine-related cancer, 1999, 6 (2), 231.

[24] Lonning P. E.: "Aromatase inhibitors and their future role in postmenopausal women with early breast cancer". Brit. J. of Cancer , 1998, 78(suppl. 4), 12.

[25] Yamamoto T., Noguchi T., Tamura T., Kitawaki J. and Okada H.: "Evidence for estrogen synthesis in adenomyotic tissues". Am. J. Obstet Gynecol., 1993, 169, 734.

[26] Miller W. R. and Langdon S. P.: "Steroid hormones and cancer III observations from human subjects". European Journal of Surgical Oncology, 1997, 23, 163.

[27] Takayama K., Zeitoun K., Gunby R., Sasano H., Bruce R. and Bulun S.: "Treatment of severe postmenopausal endometriosis with an aromatase inhibitor". Fertility and Sterility, 1998, 69 (4), 709.

[28] Bulun S. E., Zeitoun K., Takayama K., Noble L., Michael D., Simpson E. et al.: "Estrogen production in endometriosis and use of aromatase inibitors to treat endometriosis". Reviews on endocrine-related cancer, 1999, 6 (2), 293.

[29] Zeitoun K. M. and Bulun S. E.: "Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic agent". Fertility and sterility，1999, 72(6), 961.

[30] Yamamoto T., Fukuoka M., Fujimoto Y., Kitawaki J., Nakakoshi N., Yoshihama M. et al.: "Inhibitory effect of a new androstenedione derivative,14a-hydroxy-4-androstene) 3, 6, 17-trione (14a-ohat) on aromatase activity of human uterine tumors". J. Steroid Biochem., 1990, 36 (6), 517.

[31] Rose P. G., Brunetto V. L., Vanle L., Bell J., Walker J. L., Lee R. B.: "A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study". Gynecologic Oncology, 2000, 78, 212.